Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment.

Keutzer, Lina; Mockeliunas, Laurynas; Sturkenboom, Marieke G G; Bolhuis, Mathieu S; Akkerman, Onno W; Simonsson, Ulrika S H

Keutzer, Lina; Mockeliunas, Laurynas; Sturkenboom, Marieke G G; Bolhuis, Mathieu S; Akkerman, Onno W; Simonsson, Ulrika S H.

Afiliación

Keutzer L; Department of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden.
Mockeliunas L; Department of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden.
Sturkenboom MGG; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Bolhuis MS; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Akkerman OW; Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Simonsson USH; Tuberculosis Center Beatrixoord, University Medical Center Groningen, University of Groningen, 9751 ND Groningen, The Netherlands.

Pharmaceuticals (Basel) ; 16(11)2023 Nov 08.

Article en En | MEDLINE | ID: mdl-38004440

Palabras clave

Monte Carlo simulation; clinical utility index; indirect response modelling; linezolid; myelosuppression; peripheral neuropathy; pharmacokinetics; safety; time-to-event analysis; tuberculosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google